Tarsus Pharmaceuticals
TARS
256 hedge funds and large institutions have $2.98B invested in Tarsus Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 103 increasing their positions, 85 reducing their positions, and 34 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 85
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
3.91% more ownership
Funds ownership: 106.07% → 109.98% (+3.9%)
1% more funds holding
Funds holding: 253 → 256 (+3)
3% more call options, than puts
Call options by funds: $30.3M | Put options by funds: $29.5M
6% less capital invested
Capital invested by funds: $3.17B → $2.98B (-$188M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$55.1M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$54.3M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$27.3M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$24.3M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$38.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$23.2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$21.3M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$18.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.9M |
TARS Hedge Fund Activity: Q2 2026 in Review
256 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q2 2026, worth a combined $2.98B — down 5.9% from $3.17B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new TARS positions and 34 closed out — a net gain of 5 holders — while 103 added to existing stakes and 85 trimmed.
The largest buyer was Millennium Management, adding an estimated $55.1M. The largest seller was Driehaus Capital Management, cutting an estimated $38.9M.
- 256 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q2 2026, up from 253 in Q1 2026.
- Funds reported $2.98B of Tarsus Pharmaceuticals stock for Q2 2026, down 5.9% quarter-over-quarter.
- 39 funds opened new Tarsus Pharmaceuticals positions in Q2 2026 and 34 closed out, a net change of +5 holders.
- The largest Tarsus Pharmaceuticals buyer in Q2 2026 was Millennium Management, an estimated $55.1M added.
- The largest Tarsus Pharmaceuticals seller in Q2 2026 was Driehaus Capital Management, an estimated $38.9M sold.
Based on aggregated 13F filings for Q2 2026.